NCT00830674 - A Study of KRN23 in X-linked Hypophosphatemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

May 31, 2013

Conditions

X-linked Hypophosphatemia

Interventions

DRUG

Placebo

single dose IV or SC administration

DRUG

KRN23

Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg

Trial Locations (4)

Duke Clinical Research Unit, Durham

University of Texas Health Science Center at Houston, Houston

Yale University School of Medicine, New Haven

General Clinical Research Center, Indiana University School of Medicine, Indianapolis